Skip to content

Bicara Therapeutics BCAX Preferred Stock, Shares Issued

Preferred Stock, Shares Issued at other companies

Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
Summit Therapeutics logo
Summit TherapeuticsSMMT
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Operating income-$60.2M-44.2%
Net income-$56.2M-52.6%
EPS (diluted)-$0.93-36.8%

Balance sheet

See full
Cash & equivalents$323.5M-30.0%
Total debt$1.4M+144%
Total equity$514.0M+12.0%
Total assets$553.6M+15.8%

Cash flow

See full
Operating cash flow-$37.5M-33.5%
CapEx$60.0K
Free cash flow-$37.6M-33.7%

Valuation

See full
Market cap$1.68B+81.4%

Returns & leverage

See full
Return on equity-32.3%
Debt / equity0.0×
Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesIssued.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Bicara Therapeutics's preferred stock, shares issued?
Bicara Therapeutics (BCAX) reported preferred stock, shares issued of $0 in Q1 2026.